使用患者衍生细胞建模晚发性散发性阿尔茨海默病:一篇评论
Alisar Katbe1, Ismaïla Diagne1, Gilbert Bernier1,2
1Stem Cell and Developmental Biology Laboratory, Maisonneuve-Rosemont Hospital, 5690 Boulevard Rosemont, Montreal, QC H1T 2H2, Canada.
Neurology international
|January 27, 2026
概括
晚发性零星阿尔茨海默病 (LOAD) 研究正在推进新的患者衍生神经元模型. 这些模型是使用诱导多能干细胞和诱导神经元技术创建的,旨在更好地了解LOAD病理生理学.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 细胞生物学 细胞生物学
背景情况:
- 晚发性散发性阿尔茨海默病 (LOAD) 是最常见的痴呆症形式,其特征是逐渐的神经退行.
- 高度衰老是LOAD的主要风险因素,但其机制尚未完全理解.
- 现有的动物模型经常重复早期家族性阿尔茨海默病 (EOAD),限制了对LOAD的洞察力.
研究的目的:
- 审查和比较重编程技术,以生成患者特有的神经元模型的负载.
- 评估这些模型在模拟LOAD病理方面的忠实性.
- 为了进一步了解LOAD的起源和病理生理学.
主要方法:
- 对诱导多能干细胞 (iPSC) 和诱导神经元 (iN) 技术的当前文献的综述.
- 重编程方法的比较,用于生成来自患者的神经元的LOAD.
- 在生成的LOAD神经元模型中评估细胞和分子病理.
主要成果:
- 无论是iPSC技术还是iN技术,都可以产生来自患者的神经元的LOAD.
- 该研究评估了这些模型复制关键LOAD细胞和分子特征的能力.
- 讨论了关于LOAD病理的模型忠实性和模仿性的具体发现.
结论:
- 由于传统模型的局限性,患者衍生的神经元模型对于研究LOAD至关重要.
- 重编程技术为创建更准确的LOAD疾病模型提供了有希望的途径.
- 需要进一步的研究来充分验证这些模型用于LOAD药物发现和治疗开发.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.老化的老化 衰老的老化显基因组是一个表观基因组.诱导的神经元 (iN)诱导多能干细胞 (iPSC) 是一种诱导多能干细胞.神经元神经元是一个神经元.重编程是重新编程.更多相关视频
相关概念视频
01:21EPS and iPS Cells in Disease Research
3.2K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.2K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
20
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
20
01:23Alzheimer Disease ll: Pathophysiology
32
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
32